Watchlist Price Alert

Portage Biotech Inc. (PRTG)

NASDAQ: PRTG · Real-Time Price · USD

5.84

-0.19 (-3.15%)

At close: Jun 17, 2025, 1:37 PM

-3.15% (1D)

Bid	5.8
Market Cap	6.55M
Revenue (ttm)	n/a
Net Income (ttm)	-67.28M
EPS (ttm)	-68.17
PE Ratio (ttm)	-0.09
Forward PE	-0.57
Analyst	n/a

Ask	6.02
Volume	5,989
Avg. Volume (20D)	1,347,968
Open	6.00
Previous Close	6.03
Day's Range	5.83 - 6.06
52-Week Range	2.10 - 23.01
Beta	0.67

About PRTG

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRTG

Website n/a

Full Company Profile

Why Price Moved

1 month ago

+27.46%

Portage Biotech shares are trading higher after th... Unlock content with Pro Subscription

2 months ago

+103.82%

Portage Biotech shares are trading higher after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.

News

1 month ago · benzinga.com

Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human tria...

2 months ago · benzinga.com

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.

2 months ago · marketwatch.com

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.